In the Media

November 1, 2018

UBC’s Dr. Yadav Talks about How Biosynthesis May Efficiently Produce Cannabinoids

InMed and the laboratory of Dr. Vikramaditya Yadav at the University of British Columbia collaborate on a proprietary biosynthesis technology to produce bioidentical, high purity, high grade cannabinoids. The host selected is E.coli. In this video, Dr. Yadav talks how an E.coli-based system is uniquely suited for producing cannabinoids.

Source: BTV

Share this post

Latest Articles

Benzinga: Pharmaceutical Cannabinoids and their Impact on Treatments for Complex Diseases

InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, join the Benzinga Small Cap Conference Panel Discussion “Pharmaceutical Cannabinoids and their Impact on Treatments

October 6, 2021

The Dales Report – InMed Pharmaceuticals Positioned For Growth As Cannabinoid Supply Sales Poised For Imminent “Take Off”

Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, on the fast-growing synthesized cannabinoid industry and the market opportunity of rare cannabinoids.

September 22, 2021

InMed and BayMedica Host First Webinar Together Following News of Signing Definitive Agreement on Acquisition

InMed and BayMedica hosted a live webinar to talk about InMed’s acquisition of BayMedica, how it positions the company as a leader in the manufacturing

September 16, 2021